The Motley Fool · Jul 1, 2022
Investing in the Future of Food
Plus a look at what's going on with Chewy, Coinbase, and Walgreens Boots Alliance.
GM
NASDAQ · GMTX
Gemini Therapeutics, Inc.
Healthcare · Biotechnology
$1.35
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 2:44 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 25.49M
- P/E ratio
- —
- Dividend yield
- —
- 52-week range
- — – —
- Volume
- 60.42K
- Avg. volume
- 19.48K
Price performance
GMTX price history
1M range · 0 trading sessions · Daily adjusted prices
GMTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest GMTX news
The latest Smart Investors Daily articles mentioning GMTX.
Stock researchCompany · Overview
GMTX research
Overview
Company profile and research snapshot.
Company profile
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 11, 2022 | HC Wainwright & Co. | Neutral | — |
| Mar 3, 2022 | SVB Leerink | Market Perform | — |
| Mar 1, 2022 | Jefferies | Hold | — |
| Jan 24, 2022 | SVB Leerink | Outperform | — |
| Dec 20, 2021 | SVB Leerink | Outperform | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Apr 21, 2022
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.
Zacks Investment Research · Apr 12, 2022
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks Investment Research · Apr 7, 2022
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
